Neuronal Fluctuations: Learning Rates vs Participating Neurons

Deep Neural Networks (DNNs) rely on inherent fluctuations in their internal parameters (weights and biases) to effectively navigate the complex optimization landscape and achieve robust performance. While these fluctuations are recognized as crucial for escaping local minima and improving generalization, their precise relationship with fundamental hyperparameters remains underexplored. A significant knowledge gap exists concerning how the learning rate, a critical parameter governing the training process, directly influences the dynamics of these neural fluctuations. This study systematically investigates the impact of varying learning rates on the magnitude and character of weight and bias fluctuations within a neural network. We trained a model using distinct learning rates and analyzed the corresponding parameter fluctuations in conjunction with the network's final accuracy. Our findings aim to establish a clear link between the learning rate's value, the resulting fluctuation patterns, and overall model performance. By doing so, we provide deeper insights into the optimization process, shedding light on how the learning rate mediates the crucial exploration-exploitation trade-off during training. This work contributes to a more nuanced understanding of hyperparameter tuning and the underlying mechanics of deep learning.

Prostate-VarBench: A Benchmark with Interpretable TabNet Framework for Prostate Cancer Variant Classification

Variants of Uncertain Significance (VUS) limit the clinical utility of prostate cancer genomics by delaying diagnosis and therapy when evidence for pathogenicity or benignity is incomplete. Progress is further limited by inconsistent annotations across sources and the absence of a prostate-specific benchmark for fair comparison. We introduce Prostate-VarBench, a curated pipeline for creating prostate-specific benchmarks that integrates COSMIC (somatic cancer mutations), ClinVar (expert-curated clinical variants), and TCGA-PRAD (prostate tumor genomics from The Cancer Genome Atlas) into a harmonized dataset of 193,278 variants supporting patient- or gene-aware splits to prevent data leakage. To ensure data integrity, we corrected a Variant Effect Predictor (VEP) issue that merged multiple transcript records, introducing ambiguity in clinical significance fields. We then standardized 56 interpretable features across eight clinically relevant tiers, including population frequency, variant type, and clinical context. AlphaMissense pathogenicity scores were incorporated to enhance missense variant classification and reduce VUS uncertainty. Building on this resource, we trained an interpretable TabNet model to classify variant pathogenicity, whose step-wise sparse masks provide per-case rationales consistent with molecular tumor board review practices. On the held-out test set, the model achieved 89.9% accuracy with balanced class metrics, and the VEP correction yields an 6.5% absolute reduction in VUS.